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Abstract
  A series of novel quinazolines as tubulin inhibitors occupying three zones of 
colchicine domain have been designed and synthesized inspired by the recently 
disclosed crystal structure of verubulin analogue 6 with tubulin. Among the newly 
synthesized compounds, 19c showed noteworthy potency against K562, HepG2, KB, 
HCT-8 and MDB-MB-231 cancer cells. In vitro microtubule polymerization assays 
identified 19c as a potent tubulin assembly inhibitor, the binding mode of which with 
tubulin was confirmed by molecular modelling studies to occupy three zones of tubulin 
domain. Furthermore, 19c disrupted the intracellular microtubule network, caused 
G2/M phase arrest, induced cell apoptosis and depolarized mitochondria of K562 cells. 
19c also reduced the cell migration and disrupted the capillary-like tube formation of 
human umbilical vein endothelial cells (HUVECs). Importantly, 19c significantly and 
dose dependently inhibited tumor growth in H22 liver cancer xenograft mouse model. 
All these results suggested that 19c deserves further research as a novel and potential 
anti-tubulin agent for the treatment of cancers.
Key words: microtubule; tubulin inhibitor; colchicine domain; anti-vascular; anti-
  
tumor 
1. Introduction
Microtubules are ubiquitous cellular polymers that play diverse roles within the cell, 
such as maintenance of cell structure, protein trafficking, chromosomal segregation, 
and mitosis [1]. Microtubules are long and hollow structures with 5 nm walls 
surrounding a cavity, and are made up of two globular protein subunits, α- and β-tubulin 
[2-4]. Microtubule-targeting agents (MTAs) that stabilize or destabilize microtubule can 
interfere with microtubule dynamics, which leads to mitotic block and cell apoptosis. 
MTAs are divided into two classes including microtubule destabilizing agents and 
microtubule stabilizing agents [5]. At least three binding sites in tubulin including taxane, 
vinca alkaloid and colchicine binding sites, have been identified, which can be 
interfered by MTAs. The compounds targeting taxane binding site stabilize microtubule, 
while those targeting vinca alkaloid and colchicine binding sites destabilize 
microtubules [6]. Inhibitors that target colchicine binding site are characterized with 
many advantages compared with those binding another two sites, such as simpler 
structures, improved aqueous solubility, reduced toxicity and multidrug resistance 
(MDR) effects. Notably, the colchicine-site binders also exhibit antiangiogenic and 
vascular disrupting activities which are not found in other site binders [7]. Extensive 
efforts have been made to develop colchicine binding site inhibitors (CBSIs) either 
from natural products or synthetic origins, and several candidates are under clinical 
investigations as potential novel anti-cancer agents [8, 9].
Colchicine-binding domain is a deep pocket located at the α-β interface of tubulin 
heterodimers, which comprises a main site (colchicine binding site) and an additional 
neighboring pocket [10]. The colchicine domain can be divided into three zones 
including zones 1, 2 and 3 [11, 12]. Classical CBSIs are featured with an “aromatic ring - 
bridge - aromatic ring” structure character exemplified by colchicine (1) and 
combretastatin A-4 (2, CA-4) (Figure 1), and they mostly have globular or butterfly-
like shape forming a specific spatial conformation in which ring A and ring B occupy 
zone 2 and zone 1 of the colchicine domain, respectively. CBSIs that simultaneously 
occupy three zones in the cavity have been rarely reported.
ABT-751 (3), also named E7010, was a potent anti-proliferative agent firstly found 
in 1992 [13] and was subsequently identified to target the colchicine site of tubulin [14]. 
In 2009, the crystal structure of ABT-751 with tubulin was obtained and it showed that 
ABT-751 was buried more deeply than colchicine and occupied three zones of 
colchicine domain at the same time. The 4-methoylphenyl of ABT-751 is 
accommodated into zone 1 with pyridine ring in zone 2, and the phenol extends into the 
deeper site of β-tubulin, namely zone 3, forming hydrogen bond with Tyrβ202 residue 
[10]. Another reported compound that occupied all three zones of colchicine domain was 
  
4 whose m-ethoxyaniline group was extended into zone 3 of colchicine domain and 
formed hydrogen bond with Tyrβ202 [15]. Several residues in zone 2 and zone 3 differ 
among the β tubulin isotypes, which may provide opportunities to improve the 
selectivity of CBSIs to the isotype α β III tubulin isoform that is commonly 
overexpressed in cancer cells [16,17]. Thus, the above-mentioned CBSIs with unique 
binding poses may be conferred with specific targeting to tubulin isotypes, thereby 
lowering general toxicity. 
Verubulin (5) was a potent tubulin polymerization inhibitor targeting the colchicine 
binding site, and demonstrated low nanomolar potency against diverse cancer cell lines 
[18, 19]. Verubulin had entered into clinical trials for patients with advanced cancer [20], 
but had been discontinued due to cardiovascular toxicity revealed in phase I and phase 
II studies [21]. The binding mode of verubulin with tubulin was yet unknown until the 
crystal structure of tubulin in complex with verubulin analogue 6 was determined 
recently [22]. Surprisingly, the binding pose of 6 is flipped over 180° compared to the 
published molecular modeling [23, 24]. The rings A and B of compound 6 occupied zone 
2, and the rings C and D extended into zone 1 (Figure 2). The N atom at the 1-position 
of ring B interacted with the residue Cys241 via a water-mediated hydrogen bond. The 
chlorine atom at 2-position of ring B pointed to the deep pocket of β-tubulin, namely 
zone 3, reminding us that the position 2 of quinazoline may tolerate derivatization to 
extend into zone 3, thus the novel CBSIs occupy all the three zones of colchicine 
domain could be deigned. Inspired by the binding mode of ABT-751 with tubulin, 
various substituted phenyl moieties that might form hydrogen bond with Tyrβ202 
residue were introduced to the C2-position of quinazoline skeleton of verubulin (Figure 
2). Herein, we wish to report the synthesis and biological studies of these novel 
quinazoline derivatives as tubulin inhibitors occupying three zones of colchicine 
domain. 
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Figure 1. Representative tubulin inhibitors targeting colchicine binding site. Pink represents 
moieties occupying zone 1, red represents moieties occupying zone 2 and blue represents moieties 
extending into zone 3.
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Figure 2. The rational design of quinazolines as tubulin inhibitors occupying three zones of 
colchicine domain. 
2 Results and discussion
2.1 Chemistry
  Key intermediate 4-oxo-3,4-dihydroquinazoline-2-carboxylic acid ethyl ester (9) 
was synthesized via a two-step acylation/cyclization sequence using anthranilamide (7) 
as the starting material according to the literature report [25] (Scheme 1). Following 
chlorination of 9 using POCl3 afforded 10 which underwent a nucleophilic addition 
with N-methyl-4-methoxyaniline to give intermediate 11. Quinazoline-2-carboxylic 
acid (12) was obtained by esterolysis of 11, following condensation reactions with 
various anilines produced compounds 13a-c, and further deprotection of 13b gave 
compound 13d.
  Scheme 2 outlines the synthesis route of compounds 19a-t. The key intermediate 2,4-
dichloroquinazoline (17) was synthesized according to the literature report [26]. The 
starting material 2-amino-1-methyl benzoate (14) was coupled with KCNO in acetic 
acid at ambient temperature. Cyclization of methyl 2-ureidobenzoate (15) was 
processed in KOH methanol solution (pH = 10) at reflux temperature to produce 16. 
2,4-Dichloroquinazoline (17) was then achieved by refluxing 16 with POCl3 in the 
presence of DIPEA in toluene. Then, N-methyl-4-methoxyaniline was attached to the 
4-position of 2,4-dichloroquinazoline (17) through nucleophilic addition under basic 
condition in THF at room temperature to form intermediate 18. Another nucleophilic 
addition with various anilines or benzylamines under EtOH in sealed tube at 150 ℃ 
produced compounds 19a-t, and 19e was further deprotected to produce compound 19f.
Scheme 1. Synthesis of compounds 13a-da.
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Scheme 2. Synthesis of compounds 19a-ta.
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19g: n = 0, R1, R3 = H, R2 = OCH3;
19h: n = 1, R1, R3 = H, R2 = OCH3;
19i: n = 1, R1, R3 = H, R2 = F;
19j: n = 1, R1, R3 = H, R2 = OCF3;
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19l: n = 1, R1, R3 = H, R2 = OC3H7;
19m: n = 1, R1, R3 = H, R2 = CN;
19n: n = 1, R2, R3 = H, R1 = OCH3
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aReagents and conditions: (a) KNCO, AcOH, H2O, rt; (b) KOH, CH3OH, H2O, reflux; (c) POCl3, 
DIPEA, toluene, reflux; (d) N-methyl-4-methoxyaniline, Et3N, THF, rt; (e) various anilines or 
  
benzylamines, EtOH, 150 ℃, sealed tube; (f) TBAF, THF, rt.
2.2  In vitro anti-proliferative and anti-tubulin activity
The effect of linkers attached to the 2-position of quinazoline on anti-proliferative 
activity was firstly investigated. Eight compounds 13a, 13c, 13d, 19a, 19b and 19f-h 
bearing three kinds of linkers including amide bond, amino and aminomethyl were 
screened for their anti-proliferative activities in human leukemia cell lines (K562) by 
MTT assays. The results showed that compounds bearing amide bond (13a, 13c, 13d) 
and amino (19a, 19g) exhibited no obvious cytotoxicity at both 1 μM and 0.1 μM 
concentrations except 19f which had an inhibitive rate of 87.6% at 1 μM. However, 
compounds with aminomethyl as the linker (19b, 19h) exhibited significant 
cytotoxicity with the inhibitive rates of 95.3% and 80.5%, respectively at 1 μM 
concentration (see supporting information S1). Thus, aminomethyl was identified as 
the best linker that could orient additional phenyl moieties to zone 3 and was used for 
the next derivatization.
  Seventeen compounds 19b-d, 19f and 19h-t were further evaluated for their anti-
proliferative activities by MTT assays using the typical tubulin inhibitor ABT-751 that 
occupies three zones of colchicine domain as the positive control. Various hydrogen 
bond acceptors were introduced to the methylamino linker with the wish that they may 
form hydrogen bonds with the Tyrβ202 residue in zone 3, resembling the interaction of 
phenolic hydroxyl of ABT-751. As shown in Table 1, most of the compounds exhibited 
potent anti-proliferative activities. Substitutions at the 3-position of the phenyl moiety 
(19c, 19n) seem to be favorable for the improvement of activity, compound 19c bearing 
3-pyridine (IC50 = 0.10 μM) and compound 19n bearing 3-methoylphenyl (IC50 = 0.13 
μM) were about 25 folds more potent than ABT-751 (IC50 = 2.82 μM). The effect of 
substitutions at the linker on activity was also investigated, either the N-CH3 linker (19r) 
or tetrahydroisoquinoline linker (19t) led to the dramatically loss of activity while the 
methyl substitution at the methylene position (19s) maintained the activity.  
Four representative compounds 19b, 19c, 19h and 19n were chosen to evaluate their 
anti-proliferative activities against another four cancer cell lines including HepG2, KB, 
HCT-8 and MDA-MB-231 (Table 2). Interestingly, 19n was less sensitive against these 
four cancer cell lines than K562 cells with the IC50 values ranging from 0.74 to 1.17 
μM, while 19c displayed no obvious selectivity among these four cancer cell lines with 
the IC50 values ranging from 0.11 to 0.13 μM, which was about 50 folds more potent 
than ABT-751.
In vitro tubulin polymerization inhibition assays further demonstrated that 19b, 19c, 
19h and 19n were potent tubulin polymerization inhibitors. Among them, 19c (IC50 = 
2.45 μM) and 19h (IC50 = 2.67 μM) were comparable with ABT-751 (IC50 = 2.24 μM) 
  
(Table 2). Considering the good performance of 19c in both in vitro anti-proliferative 
assays and in vitro tubulin polymerization inhibition assays, it was selected for further 
biological studies.
Table 1. Anti-proliferative activities of compounds against K562 cell linea.
IC50 values (μM)b IC50 values (μM)b
Compd.
K562
Compd.
K562
19b 0.24±0.04 19m 0.37±0.02
19c 0.10±0.01 19n 0.13±0.01
19d 0.63±0.04 19o 0.56±0.02
19f 0.33±0.02 19p 0.41±0.02
19h 0.28±0.03 19q 0.85±0.05
19i 0.38±0.02 19r >5
19j 0.31±0.03 19s 0.65±0.03
19k 0.31±0.02 19t >5
19l 0.43±0.03 ABT-751 2.82±0.10
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was measured by the 
MTT assay as described in the Experimental Section.
b IC50 values are indicated as the mean ± SD (standard error) of at least three independent experiments.
Table 2. Anti-proliferative activities against four cancer cell lines a, and ITP of compounds 19b, 
19c, 19h, 19n and ABT-751.
IC50 values (μM)b
Compd.
HepG2 KB HCT-8 MDA-MB-231 ITPc
19b 0.58±0.05 0.48±0.04 0.47±0.03 0.46±0.03 5.29±0.25
19c 0.11±0.01 0.11±0.02 0.13±0.01 0.12±0.01 2.45±0.16
19h 0.21±0.02 0.37±0.03 0.48±0.01 0.47±0.05 2.67±0.18
19n 0.74±0.02 1.11±0.05 1.17±0.07 1.08±0.06 5.56±0.28
ABT-751 5.94±0.51 5.32±0.32 5.78±0.65 4.73±0.43 2.24±0.13
a Cells were treated with different concentrations of the compounds for 72 h. Cell viability was measured by the 
MTT assay as described in the Experimental Section.
b IC50 values are indicated as the mean ± SD (standard error) of at least three independent experiments.
c Inhibition of tubulin polymerization activity.
2.3 Molecular modeling 
  To validate whether 19c would occupy three zones of colchicine domain as ABT-
751, molecular modeling studies were performed. ABT-751 was firstly redocked into 
the colchicine domain resulting a similar conformation to that of ABT-751 in the crystal 
  
structure with the root mean square deviation (RMSD) value of 0.93 (PDB code: 
3HKC), which indicated the feasibility of our docking method. The docking results of 
19c displayed that it occupied three zones of colchicine domain in a similar positioning 
of ABT-751 (Figure 3A). The 4-meothylphenyl moiety of 19c located in zone 1 that 
was surrounded by residues Thr314, Lys352 and Asn258, and the quinazoline occupied 
in zone 2 with the 1-N forming a critical hydrogen bond with residue Cys241. 3-
Pyridine moiety extended into the deep pocket and was fixed by the hydrogen bond 
between N atom of pyridine and residue Tyr202. Verubulin was also docked into the 
protein which indicated that it adopted the similar location with that of verubulin 6 in 
the crystal structure (PDB code: 4I55), and 1-N formed a critical hydrogen bond with 
residue Cys241 (Figure 3B). The quinazoline moiety of 19c was highly overlapped with 
verubulin in the colchicine domain with the additional 3-pyridine moiety extended into 
zone 3. All these docking results demonstrated that 19c was a colchicine binding site 
inhibitor with a unique binding mode that it occupies three zones of colchicine domain.
Figure 3. Proposed binding models for representative compounds binding with tubulin (PDB code: 3HKC) (A)
ABT-751 (shown in blue) and 19c (shown in pink); (B) verubulin (shown in green) and 19c (shown in pink).
2.4 Anti-microtubule effect of 19c in K562 cells
Immunofluorescent assay was performed to investigate the effect of compound 19c 
on microtubule networks (Figure 4). Vehicle treated K562 cells exhibited normal 
filamentous microtubules arrays. However, when treated with 19c at three different 
concentrations (0.05 μM, 0.10 μM, and 0.20 μM) for 24 h, the microtubule networks in 
cytosol were disrupted; these results indicated that 19c can induce a dose-dependent 
collapse of the microtubule networks.
  
Figure 4. Effects of compound 19c on the cellular microtubule networks visualized by immunofluorescence. K562 
cells were treated with vehicle control 0.1% DMSO, 19c (0.05 μM, 0.1 μM, and 0.2 μM). Then, the cells were fixed 
and stained with anti-α-tubulin-FITC antibody (green), Alexa Fluor 488 dye and counterstained with DAPI (blue). 
2.5 Cell cycle analysis 
Most microtubule polymerization inhibitors alter the tubulin-microtubule 
equilibrium, causing mitotic arrest at G2/M phase and ultimately apoptotic cell death. 
Thus, the most active compound 19c was examined for its effect on cell cycle 
progression of K562 cells using propidiumiodide (PI) staining by flow cytometry 
analysis. As depicted in Figure 5, treatment with compound 19c resulted in a gradual 
accumulation of cells in the G2/M phase of cell cycle in a dose-dependent manner. The 
percentages of cells arrested at the G2/M phase increased from 15.82% to 22.86%, 
25.72%, and 27.67% at concentrations of 0, 0.05, 0.1, and 0.2 μM, respectively. These 
results demonstrated that 19c can induce cell cycle arrest at G2/M phase.
2.6 Cell apoptosis analysis
The effects of 19c on K562 cell apoptosis were further evaluated in Annexin V-FITC 
and propidium iodide (PI) staining assays and analyzed by flow cytometry (Figure 6). 
  
The percentage of apoptotic cells after 48 h treatment was only 5.74% in the control 
group. However, the total numbers of early (Annexin -V+/PI−) and late (Annexin-V+/PI+) 
apoptotic cells increased to 19.8%, 37.4% and 65.0% after treatment with 19c at 0.05, 
0.1, and 0.2 μM for 48 h, respectively. These results confirmed that 19c effectively 
induced cell apoptosis in K562 cells in a dose-dependent manner.
Figure 5． Compound 19c induced G2/M arrest in K562 cells. K562 cells were incubated with varying 
concentrations of 19c (0, 0.05, 0.1, and 0.2 μM) for 48 h. Cells were harvested and stained with PI and then analyzed 
by flow cytometry. The percentages of cells in different phases of cell cycle were analyzed by ModFit 4.1.
  
Figure 6. Compound 19c induced apoptosis in K562 cells. K562 cells were incubated with varying concentrations 
of 19c (0, 0.05, 0.1, and 0.2 μM). After 48 h of incubation, cells were collected and stained with Annexin-V/PI, 
followed by flow cytometric analysis. The percentages of cells in each stage of cell apoptosis were quantified by 
flow cytometry: (upper left quadrant) necrosis cells; (upper right quadrant) late-apoptotic cells; (bottom left quadrant) 
live cells; and (bottom right quadrant) early apoptotic cells. 
2.7 Mitochondrial membrane potential (MMP) analysis
In order to determine whether 19c-induced apoptosis was involved in a disruption of 
mitochondrial membrane integrity, the fluorescent probe JC-1 was employed to 
measure the MMP (Figure 7). When treated with 19c at concentrations of 0, 0.05, 0.10, 
and 0.20 μM for 48 h, the number of K562 cells with collapsed MMP increased from 
0.63% to 18.69%, 31.52% and 62.27%, respectively, suggesting that 19c caused 
mitochondrial depolarization of K562 cells in the process of apoptosis.
  
Figure 7. Effect of 19c on the mitochondrial membrane potential of K562 cells. Incubation with different 
concentrations (0, 0.05, 0.10, and 0.20 μM) of 19c in K562 cells for 48 h prior to staining with JC-1 dye, the number 
of cells with collapsed mitochondrial membrane potentials was determined by flow cytometry analysis.
2.8 In vitro evaluation of anti-vascular activity
To evaluate the anti-vascular activity of compound 19c, the HUVEC culture assay 
was used to assess the ability to inhibit HUVEC migration, which is the key step to 
generate new blood vessels. As shown in Figure 8A, the untreated cells migrated to fill 
the area that was initially scraped after 24 h. In contrast, compound 19c significantly 
inhibited the HUVEC migration in a dose-dependent manner. Then we further 
evaluated the anti-vascular ability of compound 19c in a tube formation assay. After 
being seeded on matrigel, HUVECs form the capillary-like tubules with multicentric 
junctions. After exposure to 19c at doses of 0.05, 0.10, and 0.20 μM for 6 h, the 
capillary-like tubes were interrupted in different levels (Figure 8B), indicating that 19c 
effectively inhibited the tube formation of HUVECs. All these results demonstrated that 
19c was a potent vascular disrupting agent.
  
Figure 8. Effects of 19c on the HUVECs migration and tube formation. (A) Scratches were created with sterile 200 
μL pipette and images were captured using phase contrast microscopy at 0 h and 24 h after treatment with 0, 0.05, 
0.1, and 0.2 μM of 19c. (B) Images depicting the formation of HUVEC capillary-like tubular network by treatment 
with 0, 0.05, 0.1, and 0.2 μM of 19c for 6h.
2.9 In vivo anti-tumor activity
To evaluate the in vivo anti-tumor efficacy of 19c, human liver cancer xenograft was 
established by subcutaneous inoculation of H22 cells into the right flank of mice. The 
tumor size and the body weights of mice were monitored and recorded every 2 days. 
Paclitaxel (PTX) was selected as the positive control. As shown in Figure 9A, the 
reduction in tumor weight reached 86.6% at a dose of 8 mg/kg/2 day (i.v.) of PTX at 
21 days after initiation of treatment as compared to vehicle. Compared with the vehicle 
group, administration of 19c at 15 and 30 mg/kg by i.v. resulted in 50.9% and 62.6% 
reduction of tumor growth, respectively (Figure 9A). Notably, no significant 
differences in body weight or other adverse effects were observed upon treatment with 
19c, while treatment with PTX led to a significant decrease of body weight (Figure 9B). 
Thus, 19c was efficacious and safe in inhibiting tumor growth with a dose-dependent 
manner in vivo and deserved further evaluation.
  
Figure 9. A) 19c treatment resulted in significantly lower tumor weight compared with controls. B) Body weight 
changes of mice during treatment.
3 Conclusions
In summary, a series of novel quinazolines occupying three zones of colchicine 
domain have been designed, synthesized inspired by the crystal structure of verubulin 
analogue 6 and tubulin. Anti-proliferative screening of these newly synthesized 
compounds validated the representative compound 19c as a high cytotoxic compound 
with IC50 values ranging from 0.10 to 0.13 μM against a panel of cancer cell lines, which 
was about 50 folds more potent than ABT-751. 19c also displayed comparable 
inhibitory activity in tubulin assembly assays to ABT-751 with the IC50 value of 2.45 
μM. The proposed binding mode of 19c with tubulin was confirmed by molecular 
modeling studies which showed that it adopted a similar positioning of ABT-751 to 
occupy three zones of colchicine domain. Further mechanism studies demonstrated that 
19c caused cell cycle arrest in G2/M phase, induced cell apoptosis and depolarized 
mitochondria of K562 cells. Moreover, 19c effectively and dose-dependently disrupted 
microtubule networks of K562 cells in immunofluorescent assays. The wound healing 
and tube formation assays also identified 19c as a potent vascular disrupting agent. 
Finally, the in vivo anti-tumor activity of 19c was validated in H22 liver cancer 
xenograft mouse model. Altogether, 19c may represent a novel class of anti-tubulin 
agent with a unique binding mode with tubulin and deserves further investigation.
4 Experimental
4.1 Chemistry
4.1.1.General
Most chemicals and solvents were purchased from commercial sources. Further 
purification and drying by standard methods were employed when necessary. 1H NMR 
and 13C NMR spectra were recorded on Bruker-300 spectrometers in the indicated 
  
solvents (TMS as internal standard). Data are reported as follows: chemical shift in ppm 
(d), multiplicity (s =singlet, d =doublet, t =triplet, q =quartet, brs = broad singlet, m 
=multiplet), coupling constant (Hz), and integration. High Resolution Mass 
measurement was performed on Agilent QTOF 6520 mass spectrometer with electron 
spray ionization (ESI) as the ion source. Purity of all tested compounds was ≥ 95%, as 
estimated by HPLC analysis. Flash column chromatography was carried out using 
commercially available silica gel (200-300 mesh) under pressure.
4.1.2. Synthesis of intermediate 12. 
  Intermediate 10 was synthesized according the procedures reported in the previous 
literature [26]. To a solution of 10 (3.62 g, 0.015 mol) and N-methyl-4-methoxyaniline 
(2.31g, 0.017 mol) in 25 mL of anhydrous isopropanol (IPA) was added 0.6 mL of 
concentrated HCl, and the mixture was stirred at room temperature overnight. The 
mixture was extracted with CH2Cl2 (3 × 50 mL). The combined organic layers were 
then washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo to 
afford crude product 11 (4.2 g, 81.6%) as yellow solid. To a solution of 11 (4.2 g, 0.012 
mol) in 20 mL CH3OH was added 20 mL 10% NaOH aqueous, and the mixture was 
stirred at 80 °C for 2 h. The CH3OH was then removed in vacuo and acidized with 10% 
HCl aqueous to pH 3. The yellow precipitates were collected by filtration, washed with 
water and dried to afford intermediate 12 (2.9 g, 76.3%) as yellow solid. 1H NMR 
(300MHz, DMSO-d6) δ7.91 - 7.83 (m, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 8.4 
Hz, 2H), 7.20 (d, J = 7.6 Hz, 1H), 7.01 (d, J = 8.3 Hz, 2H), 6.96 (d, J = 8.2 Hz, 1H), 
3.78 (d, J = 3.2 Hz, 3H), 3.57 (s, 3H);13C NMR (75 MHz, DMSO-d6) δ 165.98, 161.84, 
158.47, 153.54, 150.87, 140.55, 133.14, 128.80, 127.82, 126.75, 126.25, 115.84, 
114.16, 55.85,43.07; ESI-MS m/z 309.1 [M+Na]+ 332.1.
4.1.3. General procedures of compounds 13a-d.
  To a solution of 12 (70 mg, 0.24 mmol) in 5 mL CH3CN was added 3-
tetramethyluronium hexafluorophosphate (HATU) (94 mg, 0.27 mmol), Et3N (63 μL, 
0.48 mmol), various anilines (0.28 mmol) were added. The mixture was stirred for 1 h, 
and extracted with CH2Cl2 (3 × 25 mL). The combined organic layers were then washed 
with brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The residue was 
purified by flash column chromatography to afford the products 13a-c in 65-84% yields.
4.1.3.1 Compound 13a. White solid, yield 65.1%. 1H NMR (300 MHz, DMSO-d6) δ 
11.27 (s, 1H), 8.87 (s, 1H), 8.67 (d, J = 5.9 Hz, 2H), 8.18 (d, J = 5.8 Hz, 2H), 7.95 (d, 
J = 8.3 Hz, 1H), 7.76 (t, J = 7.6 Hz, 1H), 7.29 (d, J = 8.2 Hz, 2H), 7.24 (s, 1H), 7.06 - 
7.02 (m, 2H), 3.82 (s, 3H), 3.68 (s, 3H); 13C NMR (75 MHz, DMSO) δ 163.21, 161.39, 
158.12, 152.73, 150.62, 148.42, 146.85, 139.95, 132.76, 128.74, 127.33, 126.57, 
  
125.90, 115.76, 115.39, 114.56, 55.37, 45.82; HR-MS (ESI) m/z: calcd for C22H20N5O2 
[M+H]+ 386.1612, found 386.1606. 
4.1.3.2 Compound 13c. White solid, yield 72.0%. 1H NMR (300 MHz, CDCl3) δ 10.08 
(s, 1H), 8.05 - 7.95 (m, 1H), 7.75 (d, J = 9.0 Hz, 2H), 7.64 - 7.59 (m, 1H), 7.15 (d, J = 
8.9 Hz, 2H), 7.11 - 7.06  (m, 1H), 7.06 - 7.03 (m, 1H), 6.95 (d, J = 2.5 Hz, 2H), 6.92 
(d, J = 2.6 Hz, 2H), 3.85 (s, 3H), 3.81 (s, 3H), 3.72 (s, 3H); 13C NMR (75 MHz, CDCl3) 
δ 161.28, 160.46, 158.01, 155.88, 152.37, 151.02, 140.08, 131.82, 130.74, 128.94, 
126.93, 125.76, 125.66, 120.70, 115.77, 114.92, 113.75, 55.04, 54.99, 42.48; HR-MS 
(ESI) m/z: calcd for C24H23N4O3 [M+H]+ 415.1765, found 415.1762.
4.1.3.3 Compound 13d. 13b was obtained as colorless oil which was used for next step 
directly. To a solution of 13b (50 mg, 0.10 mmol) in THF was added TBAF (30 mg, 
0.12 mmol), and the reaction was stirred at room temperature for 30 min. Then, the 
mixture was extracted with CH2Cl2 (3 × 25 mL). The combined organic layers were 
washed with brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The 
residue was purified by flash column chromatography to afford the product 13d as 
white solid in 62.3% yield over two steps. 1H NMR (300 MHz, DMSO-d6) δ 10.34 (s, 
1H), 9.33 (s, 1H), 7.90 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 7.5 Hz, 1H), 7.67 (d, J = 8.8 
Hz, 2H), 7.29 (d, J = 7.9 Hz, 2H), 7.21 (t, J = 7.8 Hz, 1H), 7.04 (s, 1H), 7.02 (d, J = 7.9 
Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 3.80 (s, 3H), 3.65 (s, 3H); 13C NMR (75 MHz, DMSO) 
δ 161.31, 161.23, 157.96, 153.91, 153.88, 150.99, 140.26, 132.53, 130.06, 128.77, 
127.34, 126.03, 125.80, 121.76, 115.59, 115.36, 115.13, 55.37, 42.67; HR-MS (ESI) 
m/z: calcd for C23H21N4O3 [M+H]+ 401.1608, found 401.1613.
4.1.4. Synthesis of intermediate 18. 
Intermediate 17 was synthesized according the procedures reported in the previous 
literature [27]. To a solution of 17 (3.2 g, 0.016 mol) in 50 mL THF was added Et3N (3.3 
mL, 0.024 mol) and N-methyl-4-methoxyaniline (1.9 g, 0.014 mol), and the mixture 
was stirred at room temperature overnight. The mixture was extracted with CH2Cl2 (3 
× 50 mL). The combined organic layers were then washed with brine, dried over 
anhydrous Na2SO4, and concentrated in vacuo. The residue was then purified by flash 
column chromatography using PE/EA 15:1 as the fluent to afford 18 (3.9 g, 81.3%) as 
white powder. 1H NMR (300 MHz, CDCl3) δ 7.64 (d, J = 8.4 Hz, 1H), 7.47 (t, J = 7.8 
Hz, 1H), 7.07 (d, J = 8.8 Hz, 2H), 6.89 (m, 4H), 3.78 (s, 3H), 3.52 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 162.54, 158.68, 156.56, 152.98, 139.94, 132.57, 127.65, 127.49, 
126.38, 124.93, 115.44, 114.78, 55.56, 43.26; ESI-MS m/z 299.1 [M+H]+ 300.1.
4.1.5. General procedures of compounds 19a-t.
To a solution of 18 (75 mg, 0.25 mmol) in 5 mL EtOH in sealed tube was added 
various anilines or benzylamines, the mixture was stirred at 150 °C. After completion, 
the reaction was cooled to room temperature. In the cases of solid precipitation in the 
  
reaction, the precipitates were collected by filtration, washed with cold EtOH and dried 
to afford the final products. When no solid precipitated in the reaction, the solvent was 
removed in vacuo and then purified by flash column chromatography to afford the final 
products.
4.1.5.1. Compound 19a. White solid, yield 76.7%. 1H NMR (300 MHz, DMSO-d6) δ 
9.36 (s, 1H), 9.33 (s, 1H), 9.31 (s, 1H), 7.77 - 7.67 (m, 2H), 7.35 (d, J = 8.9 Hz, 2H), 
7.16 (d, J = 7.8 Hz, 2H), 7.14 - 7.10 (m, 1H), 6.86 (d, J = 8.5 Hz, 1H), 3.83 (s, 3H), 
3.65 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 161.83, 160.96, 158.52, 151.11, 150.14, 
139.04, 137.76, 129.81, 127.73, 127.61, 126.15, 125.29, 115.52, 114.53, 109.23, 55.49, 
43.25; HR-MS (ESI) m/z: calcd for C21H20N5O [M+H]+ 358.1662, found 358.1659. 
4.1.5.2. Compound 19b. White solid, yield 66.9%. 1H NMR (300 MHz, CDCl3) δ 8.56 
(d, J = 5.1 Hz, 2H), 7.57 (d, J = 8.3 Hz, 1H), 7.49 (t, J = 7.7 Hz, 1H), 7.36 (d, J = 5.1 
Hz, 2H), 7.13 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8.7 Hz, 2H), 6.87 - 6.76 (m, 1H), 6.67 
(d, J = 8.6 Hz, 1H), 4.88 (s, 1H), 4.77 (s, 2H), 3.87 (s, 3H), 3.45 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ161.35, 159.42, 149.84, 147.90, 144.14, 138.26, 134.12, 134.10, 127.46, 
127.22, 122.90, 122.06, 119.25, 115.70, 110.46, 77.48, 77.06, 76.64, 55.63, 44.13, 
43.84; HR-MS (ESI) m/z: calcd for C22H22N5O2 [M+H]+ 372.1819, found 372.1815. 
4.1.5.3. Compound 19c. White solid, yield 79.2%. 1H NMR (300 MHz, CDCl3) δ 8.58 
(s, 1H), 8.46 - 8.30 (m, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 7.36 – 
7.30 (m, 1H), 7.24 - 7.15 (m, 1H), 7.04 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 
6.65 (d, J = 6.9 Hz, 2H), 6.21 (s, 1H), 4.68 (s, 2H), 3.76 (s, 3H), 3.42 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 179.38, 161.20, 158.41, 148.44, 147.96, 138.70, 138.68, 138.64, 
134.82, 134.20, 132.87, 126.92, 126.53, 123.09, 121.51, 114.98, 110.50, 55.06, 43.07, 
42.23; HR-MS (ESI) m/z: calcd for C22H22N5O [M+H]+ 372.1819, found 372.1816.
4.1.5.4. Compound 19d. White solid, yield 75.2%. 1H NMR (300 MHz, CDCl3) δ 8.21 
(s, 1H), 7.68 (dd, J = 8.4, 2.5 Hz, 1H), 7.45 (d, J = 8.3 Hz, 1H), 7.40 - 7.34 (m, 1H), 
7.10 (d, J = 8.6 Hz, 2H), 6.94 - 6.87 (m, 2H), 6.83 (d, J = 8.4 Hz, 1H), 6.69 (m, 2H), 
6.10 (s, 1H), 4.67 (s, 2H), 3.92 (s, 3H), 3.82 (s, 3H), 3.48 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 162.99, 161.95, 157.60, 157.31, 151.59, 145.48, 140.46, 138.17, 131.73, 
127.62, 126.87, 126.25, 123.87, 120.21, 114.67, 111.76, 110.25, 55.00, 52.91, 42.48, 
42.01; HR-MS (ESI) m/z: calcd for C23H24N5O2 [M+H]+ 402.1925, found 402.1918.
4.1.5.5. Compound 19f. To a solution of 19e (50 mg, 0.10 mmol) in THF was added 
TBAF (32 mg, 0.12 mmol), and the reaction was stirred at room temperature for 30 
min. Then, the mixture was extracted with CH2Cl2 (3 × 25 mL). The combined organic 
layers were washed with brine, dried over anhydrous Na2SO4, and concentrated in 
vacuo. The residue was purified by flash column chromatography to afford the product 
19f as white solid in 46.8% yield over two steps. 1H NMR (300 MHz, DMSO-d6) δ 
10.27 (s, 1H), 9.57 (s, 1H), 7.63 (t, J = 7.8 Hz, 1H), 7.53 (d, J = 8.3 Hz, 1H), 7.42 (d, J 
= 4.9 Hz, 2H), 7.39 (d, J = 4.9 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 6.97 (t, J = 7.9 Hz, 
  
1H), 6.86 (d, J = 8.3 Hz, 2H), 6.72 (d, J = 8.5 Hz, 1H), 3.83 (s, 3H), 3.57 (s, 3H); 13C 
NMR (75 MHz, DMSO) δ 160.94, 158.90, 154.94, 138.08, 138.06, 134.25, 128.11, 
127.64, 126.97, 124.07, 123.03, 118.43, 118.32, 115.54, 115.47, 110.66, 55.51, 43.67; 
HR-MS (ESI) m/z: calcd for C22H21N4O2 [M+H]+ 373.1659, found 373.1659.
4.1.5.6. Compound 19g. White solid, yield 86.5%. 1H NMR (300 MHz, CDCl3) δ 10.48 
(s, 1H), 7.56 (d, J = 8.8 Hz, 2H), 7.48 (t, J = 7.6 Hz, 1H), 7.31 (s, 1H), 7.20 (d, J = 8.4 
Hz, 2H), 7.01 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.8 Hz, 2H), 6.82 (s, 1H), 6.67 (d, J = 
8.6 Hz, 1H), 3.88 (s, 3H), 3.80 (s, 3H), 3.62 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 
160.74, 159.22, 156.44, 150.40, 140.73, 137.21, 133.96, 129.21, 127.00, 126.85, 
123.16, 122.90, 117.78, 115.35, 113.46, 109.75, 55.17, 54.95, 43.96; HR-MS (ESI) m/z: 
calcd for C23H23N4O2 [M+H]+ 387.1816, found 387.1814. 
4.1.5.7. Compound 19h. White solid, yield 73.2%. 1H NMR (300 MHz, CDCl3) δ 7.44 
(d, J = 8.4 Hz, 1H), 7.37 (s, 1H), 7.34 (d, J = 7.8 Hz, 2H), 7.08 (d, J = 8.4 Hz, 2H), 6.88 
- 6.85 (m, 5H), 6.66 (t, J = 7.7 Hz, 1H), 5.47 (s, 1H), 4.70 (s, 2H), 3.81 (s, 3H), 3.78 (s, 
3H), 3.46 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 162.17, 158.26, 158.21, 157.30, 153.34, 
141.10, 131.66, 131.33, 128.47, 126.82, 126.18, 124.96, 119.66, 114.56, 113.38, 
112.17, 54.98, 54.78, 44.66, 42.25; HR-MS (ESI) m/z: calcd for 
C24H25N4O2[M+H]+401.1972, found 401.1968.
4.1.5.8. Compound 19i. White solid, yield 75.3%. 1H NMR (300 MHz, CDCl3) 8.64 (s, 
1H), 7.54 (d, J = 8.3 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.39 (dd, J = 8.4, 5.3 Hz, 2H), 
7.19 - 7.12 (m, 2H), 7.06 - 6.97 (m, 4H), 6.81 (t, J = 7.9 Hz, 1H), 6.67 (d, J = 8.5 Hz, 
1H), 4.73 (s, 2H), 3.87 (s, 3H), 3.57 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 163.18, 
160.76, 159.93, 158.93, 153.07, 133.59, 133.29, 128.56, 128.46, 126.96, 126.77, 
122.41, 115.21, 115.06, 114.77, 109.82, 55.14, 43.90, 43.49; HR-MS (ESI) m/z: calcd 
for C23H22FN4O [M+H]+ 389.1772, found 389.1768 .
4.1.5.9. Compound 19j. White solid, yield 83.3%. 1H NMR (300 MHz, CDCl3) δ 7.65 
(s, 1H), 7.46 (dd, J = 8.3, 1.4 Hz, 1H), 7.41 (d, J = 1.3 Hz, 1H), 7.37 (d, J = 8.4 Hz, 
2H), 7.10 (d, J = 7.7 Hz, 2H), 7.07 (d, J = 7.0 Hz, 2H), 6.90 (d, J = 8.9 Hz, 2H), 6.75 - 
6.69 (m, 1H), 6.59 (d, J = 8.6 Hz, 1H), 4.69 (s, 2H), 3.79 (s, 3H), 3.46 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 160.81, 158.90, 153.28, 147.85, 137.74, 136.58, 133.54, 128.20, 
126.96, 126.92, 126.74, 122.32, 121.61, 120.59, 120.51, 118.18, 115.19, 109.89, 55.11, 
43.83, 43.40; HR-MS (ESI) m/z: calcd for C24H22F3N4O2 [M+H]+ 455.1689, found 
455.1687.
4.1.5.10. Compound 19k. White solid, yield 82.1%. 1H NMR (300 MHz, CDCl3) δ 8.76 
(s, 1H), 7.50 (d, J = 8.3 Hz, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 8.2 Hz, 2H), 7.08 
(d, J = 8.3 Hz, 2H), 6.91 (d, J = 8.4 Hz, 2H), 6.77 (d, J = 8.3 Hz, 2H), 6.70 (d, J = 7.3 
Hz, 1H), 6.53 (d, J = 8.6 Hz, 1H), 4.61 (s, 2H), 3.92 (q, J = 6.9 Hz, 2H), 3.79 (s, 3H), 
3.52 (s, 3H), 1.31 (t, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 160.57, 159.10, 
157.77, 152.09, 140.61, 137.35, 133.81, 129.19, 128.25, 127.04, 126.77, 122.62, 
  
117.58, 115.27, 114.04, 109.48, 62.93, 55.17, 44.07, 43.70, 29.18; HR-MS (ESI) m/z: 
calcd for C25H27N4O2[M+H]+ 415.2129, found 415.2120.
4.1.5.11. Compound 19l. White solid, yield 76.5%. 1H NMR (300 MHz, CDCl3) δ 7.45 
(d, J = 8.5 Hz, 1H), 7.37 (d, J = 6.9 Hz, 1H), 7.35 - 7.30 (m, 2H), 7.09 (d, J = 8.4 Hz, 
2H), 6.89 (s, 1H), 6.89 - 6.86 (m, 2H), 6.83 (s, 2H), 6.66 (t, J = 7.7 Hz, 1H), 5.45 (s, 
1H), 4.68 (s, 2H), 4.58 - 4.48 (m, 1H), 3.81 (s, 3H), 3.46 (s, 3H), 1.32 (d, J = 6.1 Hz, 
6H); 13C NMR (75 MHz, CDCl3) δ 162.14, 158.14, 157.33, 156.51, 153.07, 141.02, 
131.39, 128.49, 126.83, 126.20, 124.81, 124.81, 119.72, 115.43, 114.57, 112.11, 69.43, 
54.99, 44.67, 42.29, 21.59; HR-MS (ESI) m/z: calcd for C26H29N4O2 [M+H]+ 429.2285, 
found 429.2275.
4.1.5.12. Compound 19m. White solid, yield 78.9%. 1H NMR (300 MHz, CDCl3) δ 
9.19 (s, 1H), 7.64 (d, J = 8.0 Hz, 2H), 7.57 - 7.49 (m, 4H), 7.17 (d, J = 8.7 Hz, 2H), 
7.01 (d, J = 8.3 Hz, 2H), 6.86 (t, J = 7.1 Hz, 1H), 6.65 (d, J = 8.6 Hz, 1H), 4.84 (d, J = 
5.9 Hz, 2H), 3.89 (s, 3H), 3.53 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.51, 159.28, 
152.35, 142.84, 142.79, 140.24, 136.95, 134.13, 131.94, 127.29, 126.93, 123.10, 
118.15, 117.51, 115.36, 110.71, 109.53, 55.18, 44.13, 43.70; HR-MS (ESI) m/z: calcd 
for C24H22N5O [M+H]+ 396.1819, found 396.1814.
4.1.5.13. Compound 19n. White solid, yield 88.1%. 1H NMR (300 MHz, CDCl3) δ 7.46 
(s, 1H), 7.35 (t, J = 7.6 Hz, 1H), 7.16 (t, J = 7.9 Hz, 1H), 7.05 (d, J = 8.4 Hz, 2H), 6.93 
(d, J = 6.8 Hz, 2H), 6.88 (d, J = 8.7 Hz, 2H), 6.74 - 6.60 (m, 3H), 5.87 (s, 1H), 4.66 (s, 
2H), 3.77 (s, 3H), 3.72 (s, 3H), 3.45 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 161.05, 
159.32, 158.56, 158.55, 139.64, 139.62, 138.43, 138.41, 133.06, 129.04, 126.97, 
126.97, 126.59, 121.75, 119.22, 115.04, 112.42, 112.34, 55.10, 54.81, 44.75, 43.23; 
HR-MS (ESI) m/z: calcd for C24H25N4O2 [M+H]+ 401.1972, found 401.1969.
4.1.5.14. Compound 19o. White solid, yield 79.2%. 1H NMR (300 MHz, CDCl3) δ 7.44 
(d, J = 8.4 Hz, 1H), 7.39 - 7.33 (m, 1H), 7.09 (d, J = 8.8 Hz, 2H), 7.01 - 6.94 (m, 2H), 
6.92 – 6.84 (m, 3H), 6.82 (d, J = 8.1 Hz, 1H), 6.69 - 6.64 (m, 1H), 5.50 (s, 1H), 4.69 (s, 
2H), 3.86 (s, 3H), 3.85 (s, 3H), 3.81 (s, 3H), 3.47 (s, 3H); 13C NMR (75 MHz, CDCl3) 
δ 162.17, 158.27, 157.32, 153.32, 148.49, 147.59, 141.04, 132.13, 131.36, 126.81, 
126.19, 124.93, 119.70, 119.39, 114.56, 112.15, 110.65, 110.61, 55.44, 55.36, 54.98, 
45.09, 42.26; HR-MS (ESI) m/z: calcd for C25H27N4O3 [M+H]+ 431.2078, found 
431.2074.
4.1.5.15. Compound 19p. White solid, yield 68.3%. 1H NMR (300 MHz, CDCl3) δ 8.96 
(s, 1H), 7.58 - 7.46 (m, 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.9 Hz, 2H), 6.88 - 
6.82 (m, 1H), 6.69 (s, 2H), 6.65 (d, J = 8.8 Hz, 1H), 4.72 (s, 2H), 3.89 (s, 9H), 3.83 (s, 
3H), 3.64 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 160.57, 159.19, 152.88, 152.23, 140.36, 
137.15, 136.69, 133.96, 132.66, 126.98, 126.89, 122.83, 117.43, 115.32, 109.48, 
103.84, 60.31, 55.79, 55.16, 44.79, 43.69; HR-MS (ESI) m/z: calcd for C26H29N4O4 
[M+H]+ 461.2183, found 461.2181.
  
4.1.5.16. Compound 19q. White solid, yield 81.4%. 1H NMR (300 MHz, CDCl3) δ 7.45 
(d, J = 8.3 Hz, 1H), 7.41 - 7.30 (m, 1H), 7.26 (s, 1H), 7.15 (d, J = 7.9 Hz, 1H), 7.09 (d, 
J = 8.6 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 6.84 (s, 1H), 6.79 – 6.62 (m, 2H), 5.63 (s, 
1H), 4.67 (s, 2H), 4.54 (t, J = 8.7 Hz, 2H), 3.81 (s, 3H), 3.48 (s, 3H), 3.16 (t, J = 8.7 
Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 162.07, 158.78, 157.78, 157.47, 140.84, 131.50, 
131.37, 127.11, 126.82, 126.75, 126.21, 124.43, 124.06, 124.06, 119.86, 114.63, 
112.00, 108.50, 70.76, 54.99, 44.89, 42.33, 29.24; HR-MS (ESI) m/z: calcd for 
C25H25N4O2 [M+H]+ 413.1972, found 413.1966.
4.1.5.17. Compound 19r. White solid, yield 76.3%. 1H NMR (300 MHz, CDCl3) δ 8.24 
(s, 1H), 7.48 - 7.42 (m, 1H), 7.26 (d, J = 8.0 Hz, 2H), 7.14 (d, J = 8.4 Hz, 2H), 6.95 (d, 
J = 8.4 Hz, 2H), 6.87 (d, J = 8.2 Hz, 2H), 6.76 (d, J = 4.0 Hz, 2H), 5.01 (s, 2H), 3.85 
(s, 3H), 3.79 (s, 3H), 3.54 (s, 3H), 3.42 (s, 3H).13C NMR (75 MHz, CDCl3) δ 160.69, 
158.52, 158.27, 141.56, 139.08, 132.73, 128.75, 128.37, 126.95, 126.10, 121.73, 
121.62, 121.49, 114.92, 113.56, 110.25, 57.71, 55.08, 54.79, 52.31, 43.02; HR-MS (ESI) 
m/z: calcd for C25H27N4O2 [M+H]+ 415.2129, found 415.2126.
4.1.5.18. Compound 19s. White solid, yield 81.2%. 1H NMR (300 MHz, CDCl3) δ 8.95 
(s, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.46 (d, J = 7.1 Hz, 1H), 7.39 (d, J = 8.3 Hz, 2H), 7.14 
(d, J = 8.7 Hz, 2H), 6.99 (d, J = 8.9 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 6.83 – 6.74 (m, 
1H), 6.59 (d, J = 8.6 Hz, 1H), 5.29 - 5.11 (m, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 3.54 (s, 
3H), 1.66 (d, J = 6.9 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 160.37, 159.10, 158.21, 
151.36, 140.40, 137.25, 135.31, 133.77, 127.00, 126.80, 126.61, 122.59, 117.37, 
115.26, 113.47, 109.36, 55.15, 54.76, 50.89, 43.66, 22.89; HR-MS (ESI) m/z: calcd for 
C25H27N4O2 [M+H]+ 415.2129, found 415.2122.
4.1.5.19. Compound 19t. White solid, yield 80.1%. 1H NMR (300 MHz, CDCl3) δ 7.52 
(d, J = 8.4 Hz, 1H), 7.37 - 7.32 (m, 1H), 7.16 (d, J = 8.3 Hz, 1H), 7.09 (d, J = 8.4 Hz, 
2H), 6.98 - 6.89 (m, 1H), 6.87 (d, J = 7.9 Hz, 2H), 6.77 (d, J = 8.3 Hz, 1H), 6.71 (s, 
1H), 6.68 - 6.56 (m, 1H), 5.01 (s, 2H), 4.19 (t, J = 5.9 Hz, 2H), 3.80 (s, 3H), 3.79 (s, 
3H), 3.54 (s, 3H), 2.96 (t, J = 5.9 Hz, 2H); 13C NMR (75 MHz, CDCl3) δ 161.75, 157.57, 
157.46, 157.30, 153.47, 141.24, 136.16, 131.23, 127.02, 126.85, 126.58, 126.07, 
125.19, 119.53, 114.56, 112.89, 111.82, 111.44, 54.98, 54.81, 45.51, 42.30, 41.10, 
29.03; HR-MS (ESI) m/z: calcd for C26H27N4O2 [M+H]+ 427.2129, found 427.2199.
4.2. Pharmacology
4.2.1. In vitro anti-proliferative assay
K562, HepG2, KB, HCT-8 and MDB-MD-231 cells were purchased from Nanjing 
KeyGen Biotech Co. Ltd. (Nanjing, China). The cytotoxicity of the test compounds was 
determined using the MTT assay. Briefly, the cell lines were incubated at 37 °C in a 
humidified 5% CO2 incubator for 24 h in 96-microwell plates. After medium removal, 
100 mL of culture medium with 0.1% DMSO containing the test compounds at different 
  
concentrations was added to each well and incubated at 37 °C for another 72 h. The 
MTT (5 mg/mL in PBS) was added and incubated for another 4 h, the optical density 
was detected with a microplate reader at 490 nm. The IC50 values were calculated 
according to the dose-dependent curves. All the experiments were repeated in at least 
three independent experiments. 
4.2.2. In vitro tubulin polymerization inhibitory assay
  An amount of 2 mg/mL tubulin (Cytoskeleton) was resuspended in PEM buffer 
containing 80 mM piperazine-N,N’-bis(2-ethanesulfonic acid) sequisodium salt PIPES 
(pH 6.9), 0.5 mM EGTA, 2 mM MgCl2, and 15% glycerol. Then the mixture was 
preincubated with compounds or vehicle DMSO on ice. PEG containing GTP was 
added to the final concentration of 3 mg/mL before detecting the tubulin polymerization 
reaction. After 30 min, the absorbance of different concentrations was detected by a 
spectrophotometer at 340 nm at 37 °C. The area under the curve was used to determine 
the concentration that inhibited tubulin polymerization by 50% (IC50), which was 
calculated with GraphPad Prism Software version 5.02.
4.2.3. Molecular modeling study
The X-ray structure of the ABT-751-α,β-tubulin complex was downloaded from the 
Protein Data Bank (PDB code: 3HKC). The protein was prepared by removal of the 
stathmin-like domain, subunits C and D, water molecules and ABT-751 using 
Discovery Studio modules. The docking procedure was performed by employing 
DOCK program in Discovery Studio 3.0 software, and the structural image was 
obtained using PyMOL software.
4.2.4. Immunofluorescence staining
K562 cells were seeded into 6-well plates and then treated with vehicle control 0.1% 
DMSO, 19c (0.05 μM, 0.1 μM, 0.2 μM) for 24 h. The cells were fixed with 4% 
paraformaldehyde and then penetrated with PBS for three times. After blocking for 20 
min by adding 50-100 μL goat serum albumin at room temperature, cells were 
incubated with a monoclonal antibody (anti-α-tubulin) at 37 °C for 2 h. Then the cells 
were washed three times by PBS following staining by fluorescence antibody and 
labeling of nuclei by 4,6-diamidino-2-phenylindole (DAPI). Cells were finally 
visualized using a fluorescence microscope (OLYMPUS, Japan).
4.2.5. Cell cycle analysis
K562 cells were seeded into 6-well plates and incubated at 37 °C in a humidified 5% 
CO2 incubator for 24 h, and then with vehicle control 0.1% DMSO, 19c (0.05 μM, 0.1 
μM, 0.2 μM) for 48 h. The collected cells were fixed by adding 70% ethanol at 4 °C for 
12 h. Subsequently, the cells were resuspended in PBS containing 100 mL RNase A 
and 400 mL of propidium iodide for 30 min. The DNA content of the cells was 
measured using a FACS Calibur flow cytometer (BectoneDickinson, San Jose, CA, 
USA).
  
4.2.6. Cell apoptosis analysis
After treatment with vehicle control 0.1% DMSO, 19c (0.05 μM, 0.1 μM, 0.2 μM) 
for 48 h, the cells were washed twice in PBS, centrifuged and resuspended in 500 mL 
AnnexinV binding buffer. The cells were then harvested, washed and stained with 5 
mL Annexin V-APC and 5 mL 7-AAD in the darkness for 15 min. Apoptosis was 
analyzed using a FACS Calibur flow cytometer (BectoneDickinson, San Jose, CA, 
USA).
4.2.7. Mitochondrial membrane potential analysis 
After treatment with vehicle control 0.1% DMSO, 19c (0.05 μM, 0.1 μM, 0.2 μM) 
for 48 h, the cells were washed in PBS and resuspended in 500 mL JC-1 incubation 
buffer at 37 °C for 15 min. Then, 19c was immediately assessed for a red fluorescence 
using a microplate reader (ELx80, Bio-Tek, USA). The fluorescent signal of monomers 
was measured with an excitation wavelength of 488 nm. The percentage of cells with 
healthy or collapsed mitochondrial membrane potentials was monitored by flow 
cytometry analysis (Bectone-Dickinson, San Jose, CA, USA).
4.2.8. Wound healing assay
K562 cells were grown in 6-well plates for 24 h. Scratches were made in confluent 
monolayers using 200 µL pipette tip. Then, wounds were washed twice with PBS to 
remove non-adherent cell debris. The media containing different concentrations (0.05 
μM, 0.1 μM, 0.2 μM) of the compound 19c were added to the petridishes. Cells which 
migrated across the wound area were photographed using phase contrast microscopy at 
0 h and 24 h. 
4.2.9. Tube formation assay
EC Matrigel matrix was thawed at 4 °C overnight, and HUVECs suspended in 
DMEM were seeded in 96-well culture plates at a cell density of 50,000 cells/well after 
polymerization of the Matrigel at 37 °C for 30 min. They were then treated with 20 μL 
different concentrations (0.05 μM, 0.1 μM, 0.2 μM) of compound 19c or vehicle for 6 
h at 37 °C. Then, the morphological changes of the cells and tubes formed were 
observed and photographed under inverted microscope (OLYMPUS, Japan).
4.2.10. In vivo anti-tumor evaluation
Five-week-old male Institute of Cancer Research (ICR) mice were purchased from 
Shanghai SLAC Laboratory Animals Co. Ltd. A total of 1 × 106 H22 cells were 
subcutaneously inoculated into the right flank of ICR mice according to protocols of 
tumor transplant research, to initiate tumor growth. After incubation for one day, mice 
were weighted and at random divided into four groups of eight animals. The groups 
treated with 19c were administered 15, 30 mg/kg in a vehicle of 10% DMF/2% Tween 
80/88% saline, respectively. The positive control group was treated with PTX (8 mg/kg) 
every 2 days by intravenous injection. The negative control group received a vehicle of 
10% DMF/2% Tween 80/88% saline through intravenous injection. Treatments of 19c 
  
were done at a frequency of intravenous injection one dose per day for a total 21 
consecutive days while the positive group was treated with PTX one dose per two days. 
The mice were sacrificed after the treatments and the tumors were excised and weighed. 
The inhibition rate was calculated as follows: Tumor inhibitory ratio (%) = (1-average 
tumor weight of treated group/average tumor weight of control group) × 100%.
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Highlights:
 A series of quinazolines have been designed to occupy three zones of colchicine domain. 
 19c showed the most potent in vitro anti-proliferative activity.
 19c was identified as a tubulin polymerization inhibitor with potent vascular disrupting activity.
 19c was validated to occupy three zones of colchicine domain on in silico studies.
 19c exhibited potent tumor growth inhibition in H22 liver cancer xenograft mouse model.
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